A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- breast tumor must have been determined to be estrogen receptor (ER)-and progesterone receptor (PgR)-negative - tumor must have been determined to be human epidermal growth factor receptor 2 (HER2)-negative - surgery (mastectomy (total, skin-sparing, or nipple-sparing) or lumpectomy) completed no more than 60 days from enrollment

Exclusion Criteria:

- T4 tumors including inflammatory breast cancer - clinical or radiologic evidence of metastatic disease - previous history of invasive breast cancer or DCIS in the same breast - Chemotherapy administered for the currently diagnosed breast cancer prior to randomization

Conditions & Interventions

Interventions:
Drug: Carboplatin, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel
Conditions:
Cancer
Keywords:
Breast Cancer, Breast Cancer, Triple Negative Breast Cancer

More Information

Description: We are studying the addition of a drug to the treatment for people who have triple-negative breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells. Some people will receive the current treatment and others will have the current treatment with carboplatin added. The results of the two treatments will be compared.
Study Contact: Kristen Nelson - knelso65@fairview.org
Principal Investigator: Edward Greeno, M.D.
IRB Number: MMCORC003